IHC - WT-1

This test is generally performed when a patient has been diagnosed with a tumor, and there is a need to identify the primary site, particularly when a kidney or ovarian origin is suspected.

The IHC - WT-1 test identifies the presence of the WT-1 protein in tissue samples. A positive result can suggest that the sampled tumor originated from kidney or ovarian tissues, helping to classify the type of cancer.

The frequency of this test is based on the individual's clinical circumstances and should be advised by their healthcare provider.

In tissue samples, 'normal' values are not strictly applicable. The interpretation of results should be performed by a healthcare provider in the context of the patient's overall clinical picture.

No special precautions are necessary before this test. Patients should continue with their usual diet and medications unless instructed otherwise by their healthcare provider.

WT-1 levels can be influenced by the presence and type of cancer, specifically kidney and certain types of ovarian cancers.

If your test results are abnormal, it is advisable to discuss them with an oncologist or the healthcare provider who ordered the test. They can interpret the results in the context of your overall health condition and guide further investigations or treatments as required.

The risks associated with this test primarily involve the biopsy procedure used to obtain the tissue sample. These may include discomfort, bleeding, or infection.

Currently, there are no known medications that specifically influence WT-1 levels.

While the primary use of the IHC - WT-1 test is in the diagnosis and classification of certain cancers, it may also be utilized in specific clinical situations or research as determined by a healthcare provider.

A positive result for the IHC - WT-1 test indicates the presence of the WT-1 protein in the tissue sample. This result can suggest the presence of certain types of cancers, particularly Wilms' tumor or certain ovarian cancers. However, further interpretation should be made by a healthcare provider considering the overall clinical context.

Yes, the IHC - WT-1 test is often part of a larger panel of tests, including other IHC markers and possibly genetic tests, to diagnose and classify tumors accurately.

This test is performed by a pathologist in a laboratory setting.

Yes, this test can be performed on both men and women if there is a need to evaluate for certain types of tumors. However, since WT-1 is often used in diagnosing certain ovarian cancers, it may be more commonly used in women.

While the primary use of the IHC - WT-1 test is in the assessment of certain cancers, it may be used in other specific clinical situations or research as determined by a healthcare provider.

While maintaining a healthy lifestyle is always beneficial, it does not directly influence WT-1 levels, which are primarily determined by the presence of specific cancers.

The test itself is not painful. However, the biopsy procedure used to obtain the tissue sample can cause some discomfort.

The IHC - WT-1 test can provide useful information for the classification of certain cancers, which can guide treatment decisions. However, individual responses to treatment involve many factors and should be discussed with your healthcare provider.

In summary, the IHC - WT-1 Diagnostic Test is an essential tool in the diagnosis and management of certain types of cancers, particularly Wilms' tumor and certain ovarian cancers. Always consult your healthcare provider for a thorough interpretation of your test results and guidance on the next steps for your health journey.